---
title: "Molgramostim Inhalation Solution: Autoimmune pulmonary alveolar proteinosis"
description: "Formulary evidence on Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis. Clinical evidence covers IMPALA-2, IMPALA, IMPALA-X, SAV006-04, Long-term outcomes in five patients with Autoimmune pulmonary alveolar proteinosis treated with Molgramostim Inhalation Solution, and MOL-001. 197 evidence topics quoted from 85 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Molgramostim Inhalation Solution: Autoimmune pulmonary alveolar proteinosis

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Molgramostim

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of Autoimmune pulmonary alveolar proteinosis

<a id="topic-1.1.1-1"></a>

##### Summary

A Japanese registry reported a minimum incidence of 0.49 per million and prevalence of 6.2 per million for autoimmune pulmonary alveolar proteinosis. Reported symptoms include shortness of breath, cough, fatigue, and reduced exercise capacity. In a retrospective cohort of 104 participants with autoimmune pulmonary alveolar proteinosis, 35 (34%) were hospitalized because of infection.

Source: [Inoue et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2720118/); [Savara Inc. autoimmune PAP disease page](https://savarapharma.com/our-science/what-is-apap/); [Mabo et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37758458/)

<a id="heading-1.1.2"></a>

#### 1.1.2 Molgramostim Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary

IMPALA-2 randomized 164 participants, 81 to molgramostim and 83 to placebo. At week 24, the reported change in DLCO percent predicted was 9.8% with molgramostim and 3.8% with placebo, an estimated treatment difference of 6.0 percentage points (P<0.001). The SGRQ Total Score comparison had P=0.0072; the SGRQ Activity Score comparison had nominal P=0.0149 but was not statistically significant under the prespecified testing hierarchy. In the 48-week safety report, symptomatic COVID-19 infection occurred in 22% versus 10% and diarrhea in 11% versus 2%, respectively. No deaths were reported.

Source: [Savara Inc. NEJM IMPALA-2 publication announcement (2025)](https://investors.savarapharma.com/news/news-details/2025/New-England-Journal-of-Medicine-NEJM-to-Publish-Results-From-Savaras-Pivotal-Phase-3-IMPALA-2-Clinical-Trial-in-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP/default.aspx); [Ataya et al. (2025b)](https://savarapharma.com/wp-content/uploads/Ataya-QoL-PRO-ATS-2025-Poster-FINAL.pdf); [Trapnell et al. (2024b)](https://savarapharma.com/wp-content/uploads/IMPALA-2-ERS-2024-Poster-FINAL.pdf)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Molgramostim

<a id="topic-1.1.3-1"></a>

##### Summary

No product-specific budget impact model is included in this report. The Dutch horizon scan gives an expected annual cost per patient of €100,000–500,000. This is a horizon-scan estimate, not an observed U.S. average sales price or an announced U.S. wholesale acquisition cost.

Source: [National Health Care Institute Horizonscan Geneesmiddelen (2026)](https://www.horizonscangeneesmiddelen.nl/geneesmiddelen/molgramostim?versie=versie-7)

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary

The phase 3 evidence supports an effect on pulmonary gas transfer at 24 weeks. Savara’s August 2026 update continued to identify MOLBREEVI as unapproved, with regulatory applications under review. The reported November 22, 2026 FDA target action date is not an approval date. The clinical results and the available horizon-scan cost estimate do not establish a product-specific budget impact.

Source: [Savara Inc. NEJM IMPALA-2 publication announcement (2025)](https://investors.savarapharma.com/news/news-details/2025/New-England-Journal-of-Medicine-NEJM-to-Publish-Results-From-Savaras-Pivotal-Phase-3-IMPALA-2-Clinical-Trial-in-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP/default.aspx); [Savara Inc. second quarter 2026 results announcement (2026)](https://investors.savarapharma.com/news/news-details/2026/Savara-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update/default.aspx); [Savara Inc. BLA review extension announcement (2026)](https://investors.savarapharma.com/news/news-details/2026/Savara-Announces-the-U-S--Food--Drug-Administration-FDA-Has-Extended-the-Review-Period-for-the-Molgramostim-Inhalation-Solution-Molgramostim-Biologics-License-Application-BLA-in-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP/default.aspx); [National Health Care Institute Horizonscan Geneesmiddelen (2026)](https://www.horizonscangeneesmiddelen.nl/geneesmiddelen/molgramostim?versie=versie-7)

## Related pages
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Terms and abbreviations](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/terms-and-abbreviations.md)
- [Molgramostim Inhalation Solution: Autoimmune pulmonary alveolar proteinosis](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/executive-summary.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Product information and disease description](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/product-information-and-disease-description.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Clinical evidence](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/clinical-evidence.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Economic information and modeling report](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/economics) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/economics.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: References](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/references) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/references.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: prevalence by geography](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/prevalence) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/prevalence.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/cost-effectiveness-analyses.md)
